X

Xilio Therapeutics

Developer of tumor-activated immuno-oncology therapies.

Senior Research Associate - Immunology

Translational Research & Bench BiologyPosted on Nov 17
Full-timeWaltham, MA, USA$90.5k - $103.5k /yr

About the Job

Requirements

  • A Bachelor of Arts degree and 2–4 years of post-graduate biotechnology or pharmaceutical experience or related-subject experience, or a Master of Science degree and 1 year of industry experience.
  • Experience with primary mammalian cell culture and aseptic technique is desired.
  • Familiarity with the development and execution of immunological in vitro assays is preferred.
  • Experience with enzyme-linked immunosorbent assay (ELISA) is desired.
  • Experience with single-color flow cytometry is preferred.
  • Be goal-oriented and organized, manage multiple projects, and execute work to timelines that meet company goals.
  • Be willing to learn new techniques and skills.
  • Work well in a cross-functional team environment, independently, and while helping others.
  • Have excellent verbal and written communication skills.

Responsibilities

  • Work closely with colleagues in immunology, cell pharmacology, and the broader research organization to support discovery and development programs.
  • Design and perform assays, analyze data using appropriate statistical analyses, and present results.
  • Work as an integrated member of the research team to generate data supporting ongoing drug discovery efforts.
  • Contribute to key project team decisions and translational studies for development-stage assets.
  • Manage and organize primary cell banks.
  • Manage, organize, and expand immortalized cell lines and primary T cells.
  • Capture detailed experimental information in electronic lab notebook (ELN) entries.
  • Participate regularly and present data and analyses at immunology team and department meetings.

About the Company

Xilio Therapeutics

Developer of tumor-activated immuno-oncology therapies.

Xilio Therapeutics develops tumor-activated immuno-oncology therapies for solid tumors. Its approach uses a proprietary platform to create antibodies, cytokines, bispecifics, and cell engagers that localize anti-tumor activity within the tumor microenvironment, reducing systemic side effects while maintaining efficacy. The company’s products work by activating the immune response primarily inside tumors, rather than throughout the body. This focus on tumor-activated design and a broad immuno-oncology pipeline helps Xilio stand apart from competitors, which often rely on conventional systemic therapies. The goal is to improve cancer treatment by providing therapies that are effective, tolerable, and durable for patients, with revenue coming from partnerships, licensing agreements, and potential future sales of approved therapies.

Company size
51-200
Company stage
IPO
Headquarters
Waltham, MA
Founded
2016

Recently Posted Jobs

Explore more opportunities at Xilio Therapeutics

See more jobs